Tailoring Peptidomimetics for Targeting Protein-Protein Interactions

被引:38
作者
Akram, Omar N. [1 ]
DeGraff, David J. [7 ]
Sheehan, Jonathan H. [4 ]
Tilley, Wayne D. [5 ,6 ]
Matusik, Robert J. [3 ]
Ahn, Jung-Mo [2 ]
Raj, Ganesh V. [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA
[2] Univ Texas Dallas, Dept Chem, Richardson, TX 75083 USA
[3] Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN USA
[4] Vanderbilt Univ, Dept Biochem, Struct Biol Ctr, Nashville, TN 37232 USA
[5] Univ Adelaide, Sch Med, Canc Res Ctr, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia
[6] Univ Adelaide, Sch Med, Canc Res Ctr, Adelaide Prostate, Adelaide, SA, Australia
[7] Penn State Coll Med, Milton S Hershey Med Ctr, Hershey, PA USA
基金
英国医学研究理事会;
关键词
CANCER STEM-CELLS; RESISTANT PROSTATE-CANCER; ANDROGEN RECEPTOR; ALPHA-HELIX; INTERACTION NETWORK; INTERACTION SITES; INDUCED APOPTOSIS; DRUG DISCOVERY; OVARIAN-CANCER; HIGH-AFFINITY;
D O I
10.1158/1541-7786.MCR-13-0611
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Protein-protein interactions (PPI) are a hallmark of cellular signaling. Such interactions occur abundantly within the cellular milieu and encompass interactions involved in vital cellular processes. Understanding the various types, mechanisms, and consequences of PPIs with respect to cellular signaling and function is vital for targeted drug therapy. Various types of small-molecule drugs and targeted approaches to drug design have been developed to modulate PPIs. Peptidomimetics offer an exciting class of therapeutics as they can be designed to target specific PPIs by mimicking key recognition motifs found at critical points in the interface of PPIs (e.g., hotspots). In contrast to peptides, peptidomimetics do not possess a natural peptide backbone structure but present essential functional groups in a required three-dimensional pattern complimentary to the protein-binding pocket. This design feature overcomes many limitations of peptide therapeutics including limited stability toward peptidases, poor transport across biologic membranes, and poor target specificity. Equally important is deciphering the structural requirements and amino acid residues critical to PPIs. This review provides an up-to-date perspective of the complexity of cellular signaling and strategies for targeting PPIs in disease states, particularly in cancer, using peptidomimetics, and highlights that the rational design of agents that target PPIs is not only feasible but is of the utmost clinical importance. (C) 2014 AACR.
引用
收藏
页码:967 / 978
页数:12
相关论文
共 106 条
[1]  
Ahn JM, 2011, P 22 AM PEPT S, P178
[2]   Peptidomimetics and Peptide Backbone Modifications [J].
Ahn, Jung-Mo ;
Boyle, Nicholas A. ;
MacDonald, Mary T. ;
Janda, Kim D. .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2002, 2 (05) :463-473
[3]   Evaluation of Androgenic Activity of Nutraceutical-Derived Steroids Using Mammalian and Yeast in Vitro Androgen Bioassays [J].
Akram, Omar N. ;
Bursill, Christina ;
Desai, Reena ;
Heather, Alison K. ;
Kazlauskas, Rymantas ;
Handelsman, David J. ;
Lambert, Gilles .
ANALYTICAL CHEMISTRY, 2011, 83 (06) :2065-2074
[4]   AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer [J].
Anzick, SL ;
Kononen, J ;
Walker, RL ;
Azorsa, DO ;
Tanner, MM ;
Guan, XY ;
Sauter, G ;
Kallioniemi, OP ;
Trent, JM ;
Meltzer, PS .
SCIENCE, 1997, 277 (5328) :965-968
[5]   Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ [J].
Arnt, CR ;
Chiorean, MV ;
Heldebrant, MV ;
Gores, GJ ;
Kaufmann, SH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (46) :44236-44243
[6]   BAG1: The Guardian of Anti-Apoptotic Proteins in Acute Myeloid Leukemia [J].
Aveic, Sanja ;
Pigazzi, Martina ;
Basso, Giuseppe .
PLOS ONE, 2011, 6 (10)
[7]  
Azzarito V, 2013, NAT CHEM, V5, P161, DOI [10.1038/NCHEM.1568, 10.1038/nchem.1568]
[8]   Strategies to search and design stabilizers of protein-protein interactions: A feasibility study [J].
Block, Peter ;
Weskamp, Nils ;
Wolf, Alexander ;
Klebe, Gerhard .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2007, 68 (01) :170-186
[9]   A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells [J].
Bockbrader, KM ;
Tan, MJ ;
Sun, Y .
ONCOGENE, 2005, 24 (49) :7381-7388
[10]   Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: Degarelix [J].
Broqua, P ;
Riviere, PJM ;
Conn, PM ;
Rivier, JE ;
Aubert, ML ;
Junien, JL .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (01) :95-102